Dalteparin

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1690 publications

During pregnancy, anticoagulant effect of low molecular weight heparin can be determined with both thrombelastography and anti-factor Xa activity, or not?

During pregnancy, anticoagulant effect of low molecular weight heparin can be determined with both thrombelastography and anti-factor Xa activity, or not?

Journal: Anaesthesia and intensive care

Published: July 11, 2026

Livedoid Vasculopathy in a Female Patient With a History of COVID-19 Infection During Pregnancy: A Case Report.

Livedoid Vasculopathy in a Female Patient With a History of COVID-19 Infection During Pregnancy: A Case Report.

Journal: Acta dermatovenerologica Croatica : ADC

Published: June 26, 2026

Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs.

Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs.

Journal: Research and practice in thrombosis and haemostasis

Published: April 06, 2026

Cerebral venous thrombosis in pregnancy.

Cerebral venous thrombosis in pregnancy.

Journal: BMJ case reports

Published: March 25, 2026

In vitro comparison of the effects of abelacimab, dalteparin, and apixaban on catheter-induced clotting and thrombin generation.

In vitro comparison of the effects of abelacimab, dalteparin, and apixaban on catheter-induced clotting and thrombin generation.

Journal: Research and practice in thrombosis and haemostasis

Published: March 18, 2026

Pharmacological thromboprophylaxis in hospitalized patients with acute infectious diseases: a meta-analysis.

Pharmacological thromboprophylaxis in hospitalized patients with acute infectious diseases: a meta-analysis.

Journal: European journal of clinical pharmacology

Published: February 24, 2026

Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.

Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.

Journal: Journal of clinical medicine

Published: February 19, 2026

Heparin-like compounds improve the biophysical properties of eosinophilic mucus.

Heparin-like compounds improve the biophysical properties of eosinophilic mucus.

Journal: Allergology international : official journal of the Japanese Society of Allergology

Published: February 10, 2026

Impact of postoperative weight loss on anticoagulant dosing after major lower limb amputation.

Impact of postoperative weight loss on anticoagulant dosing after major lower limb amputation.

Journal: Annals of the Royal College of Surgeons of England

Published: January 20, 2026

Discovery of a Piperazine-Based Quaternary Ammonium Macrocycle as a Universal Reversal Agent for Heparin Anticoagulants.

Discovery of a Piperazine-Based Quaternary Ammonium Macrocycle as a Universal Reversal Agent for Heparin Anticoagulants.

Journal: Journal of medicinal chemistry

Published: January 07, 2026

Prophylaxis for venous thromboembolism in traumatic brain injury: protocol for a randomised controlled trial.

Prophylaxis for venous thromboembolism in traumatic brain injury: protocol for a randomised controlled trial.

Journal: BMJ open

Published: December 26, 2025

Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome.

Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome.

Journal: Kidney medicine

Published: December 03, 2025

Showing 1-12 of 1,690

Last Updated: 09/26/2026